title: [Expression of SDF-1 in lung tissues and intervention of AMD3100 in asthmatic rats].
abstract: OBJECTIVE
  To study the expression of stromal cell derived factor-1(SDF-1) in the airway and to investigate the role of SDF-1 receptor antagonist AMD3100 intervention in rats with asthma.
  
  
  METHODS
  Thirty Sprague-Dawley rats were randomly divided into three groups: normal control and asthma with and without AMD3100 intervention. The rat model of asthma was prepared by aerosolized ovalbum (OVA) challenge. The AMD3100 intervention group was administered with AMD3100 of 50 μg 30 minutes before challenge every other day, for 10 times. The characteristic airway inflammation and alterations of airway structures were observed by hemetoxylin and eosin staining. The levels of interleukin 4 and interleukin 5 in whole lung homogenates were measured using ELISA. RT-PCR was used to evaluate the expression of SDF-1 mRNA in the lung.
  
  
  RESULTS
  The airway wall thickness in the untreated asthma group was greater than that in the control and the AMD3100 intervention groups (P<0.05). The levels of interleukin 4 and interleukin 5 in whole lung homogenates in the AMD3100 intervention group were lower than those in the untreated asthma group (P<0.05). The expression of SDF-1 mRNA in the untreated asthma group was higher than that in the control and the AMD3100 intervention groups (P<0.05).
  
  
  CONCLUSIONS
  SDF-1 may be associated with airway inflammation and remodeling in rats with asthma. AMD3100 may reduce the airway inflammation and improve airway remodeling by inhibiting the bioactivity of SDF-1.
authors.affiliation: Department of Pediatrics, Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China. zlpwlx@163.com
authors.forename: Li-Ping
authors.initials: LP
authors.lastname: Zou
authors.forename: Li-Xia
authors.initials: LX
authors.lastname: Wang
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhang
authors.forename: Wen-Li
authors.initials: WL
authors.lastname: DU
mesh_terms: D000818:Animals; D001249:Asthma / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism; D001596:Benzylamines; D054377:Chemokine CXCL12 / Q000032:analysis / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D000080027:Cyclams; D005260:Female; D006571:Heterocyclic Compounds / Q000494:pharmacology*; D015847:Interleukin-4 / Q000032:analysis; D015848:Interleukin-5 / Q000032:analysis; D008168:Lung / Q000378:metabolism* / Q000473:pathology; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors*
chemical_list: D001596:Benzylamines; D054377:Chemokine CXCL12; D000080027:Cyclams; D006571:Heterocyclic Compounds; D015848:Interleukin-5; D012333:RNA, Messenger; D019718:Receptors, CXCR4; D015847:Interleukin-4; C088327:plerixafor